niclosamide (HAB-SON01) / Hyundai Biosci - LARVOL DELTA

Hyundai ADM, ’HAB-SON01’ Combination Therapy Phase 1 IND Application [Google translation] (Medipana) - "Hyundai ADM...applied for an Investigational New Drug (IND) phase 1 clinical trial plan approval (IND) to the Ministry of Food and Drug Safety on the 18th to confirm whether the anticancer effect of its niclosamide metabolism-modulating anticancer drug 'HAB-SON01' when administered in combination with the existing anticancer drug docetaxel is greater than when the existing anticancer drug is administered alone....As a result of an animal experiment on triple-negative breast cancer conducted with HAB-SON01, it was confirmed that the ‘HAB-SON01 and chemotherapy docetaxel combination group’ had a 67% greater anticancer effect than the ‘docetaxel monotherapy group.’....This clinical trial is a test to confirm whether 'HAB-SON01, when administered in combination with existing anticancer drugs, can overcome the problem of cancer cell resistance to existing anticancer drugs and have a better anticancer effect..."

New P1 trial • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer